Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan.

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Tune Therapeutics’ co-founders, from left: Akira Matsuno, chief financial officer; Charles Gersbach; and Fyodor Urnov, who also serves on the startup’s scientific advisory board. (Tune Photos ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...

The company’s leading therapeutic candidate, Tune-401, has now been approved for clinical trials in both Hong Kong and New Zealand Leading epigenetic therapy company Tune Therapeutics announced ...

DURHAM, N.C. & SEATTLE, January 13, 2025--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise ...